{"analyses":[{"ciLowerLimit":"71.2","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"143.6","estimateComment":"Ratio of geometric mean is calculated as Azacitidine 50 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance model on the nature log-transformed CL/F obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"101.1"},{"ciLowerLimit":"103.6","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"202.7","estimateComment":"Ratio of geometric mean is calculated as Azacitidine 75 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance model on the nature log-transformed CL/F obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"144.9"},{"ciLowerLimit":"71.4","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"143.9","estimateComment":"Ratio of geometric mean is calculated as Azacitidine 100 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance model on the nature log-transformed CL/F obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"101.4"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.00","value":"104.58"},{"groupId":"OG001","spread":"17.03","value":"105.76"},{"groupId":"OG002","spread":"30.88","value":"151.55"},{"groupId":"OG003","spread":"25.64","value":"106.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"The apparent total clearance of azacitidine after a single dose on Day 1, calculated as Dose/AUC0-inf.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function (defined as creatinine clearance \\> 80 mL/min/1.73m\\^2) received a single subcutaneous dose of azacitidine 25 mg/m\\^2 on Day 1.","id":"OG000","title":"Azacitidine 25 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\\^2 on Day 1.","id":"OG001","title":"Azacitidine 50 mg/m^2"},{"description":"Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"OG002","title":"Azacitidine 75 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\\^2 on Day 1.","id":"OG003","title":"Azacitidine 100 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants with normal renal function only.","reportingStatus":"POSTED","timeFrame":"Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose","title":"Apparent Total Clearance of Azacitidine (CL/F)","type":"PRIMARY","unitOfMeasure":"liters/hour"}